Zobrazeno 1 - 10
of 241
pro vyhledávání: '"Peter M. Voorhees"'
Autor:
Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, Jinming Song, Carlos M. Morán-Segura, Jonathan V. Nguyen, Lazaros Lekakis, Sebastian Fernandez-Pol, Annie N. Samraj, Kikkeri N. Naresh, Mariola Vazquez-Martinez, Rachid C. Baz, Jay Y. Spiegel, Lekha Mikkilineni, John M. Gubatan, Surbhi Sidana, Andre de Menezes Silva Corraes, Nilesh M. Kalariya, Krina K. Patel, Kevin G. Shim, Rafael Fonseca, Christopher Ferreri, Peter M. Voorhees, Shambavi Richard, Cesar Rodriguez Valdes, Sireesha Asoori, Jeffrey L. Wolf, Andrew J. Cowan, Douglas W. Sborov, Frederick L. Locke, Yi Lin, Yinghong Wang, Doris K. Hansen
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtag
Externí odkaz:
https://doaj.org/article/785e1008853f44f183853c5a67a48d03
Autor:
Ajai Chari, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up
Externí odkaz:
https://doaj.org/article/bb6796db0ba84a22b84787f34a884f56
Autor:
Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob Laubach, Timothy M. Schmidt, Douglas W. Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Bhagirathbhai R. Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/
Externí odkaz:
https://doaj.org/article/ebc38d6b2c3c4c4a957f6410c2bc2f56
Autor:
Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castaneda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher J. Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B. Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/3e7b6b54104143d6819770a8ea596373
Autor:
Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed cl
Externí odkaz:
https://doaj.org/article/ba30b147cb5a40229e9257f0ed0c5838
Autor:
Hamid Ehsan, Myra Robinson, Peter M. Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A. Paul
Publikováno v:
Life, Vol 14, Iss 3, p 384 (2024)
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which increases nuclear retention of tumor suppressor proteins (TSPs), i
Externí odkaz:
https://doaj.org/article/bb9f798d753b484da7597fbdf139c831
Autor:
Zainab Shahid, Alicia L. Patrick, Michelle L. Wallander, Erin E. Donahue, Sally J. Trufan, Antoinette R. Tan, Jimmy J. Hwang, Earle F. Burgess, Brittany Ragon, Nilanjan Ghosh, Michael R. Grunwald, Peter M. Voorhees, Edward A. Copelan, Derek Raghavan
Publikováno v:
Vaccine: X, Vol 14, Iss , Pp 100289- (2023)
Purpose: Cancer patients are at high risk of developing severe illness from SARS-CoV-2 infection, but risk is lowered with receipt of COVID-19 vaccine. COVID-19 vaccination uptake among previously infected cancer patients may be influenced by an assu
Externí odkaz:
https://doaj.org/article/b5e30d5ae392467681a5ca38f490956d
Autor:
David Foureau, Manisha Bhutani, Fei Guo, Katherine Rigby, Marina Leonidas, Elise Tjaden, Andee Fox, Shebli Atrash, Barry Paul, Peter M. Voorhees, Saad Z. Usmani
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 6933-6936 (2021)
Externí odkaz:
https://doaj.org/article/9995971983e1459cb5f33ecbf93952fc
Autor:
Rafael Fonseca, Saad Z. Usmani, Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Cote, Annette Lam, Jon Ukropec, Eric M. Maiese, Sandhya Nair, Ravi Potluri, Peter M. Voorhees
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities.
Externí odkaz:
https://doaj.org/article/0f1b33e8ad784fecbc53fa0b5af5dc8f
Autor:
David M. Foureau, Manisha Bhutani, Myra Robinson, Fei Guo, Duy Pham, Ben Buelow, Nury Steuerwald, Katherine Rigby, Elise Tjaden, Marina Leonidas, Barry A. Paul, Shebli Atrash, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 113-121 (2020)
Abstract TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients
Externí odkaz:
https://doaj.org/article/9eb554299b834585993fcebfa249976e